

Nicolaus Andratschke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8927328/publications.pdf>

Version: 2024-02-01

133
papers

4,164
citations

117625

34
h-index

138484

58
g-index

139
all docs

139
docs citations

139
times ranked

4374
citing authors

#	ARTICLE	IF	CITATIONS
1	ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 11-17.	0.6	230
2	Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non-Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1050-1058.	1.1	179
3	ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 193-198.	2.0	143
4	Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases: A pooled analysis of the German working group for stereotactic radiotherapy. <i>Lung Cancer</i> , 2016, 97, 51-58.	2.0	128
5	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. <i>JAMA Oncology</i> , 2020, 6, 1028.	7.1	122
6	The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. <i>BMC Cancer</i> , 2018, 18, 283.	2.6	115
7	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer: The ETOP NICOLAS trial. <i>Lung Cancer</i> , 2019, 133, 83-87.	2.0	113
8	Current status of angiogenesis inhibitors combined with radiation therapy. <i>Cancer Treatment Reviews</i> , 2006, 32, 348-364.	7.7	109
9	Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: Patterns of failure. <i>Radiotherapy and Oncology</i> , 2011, 101, 245-249.	0.6	106
10	Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. <i>Radiation Oncology</i> , 2015, 10, 100.	2.7	104
11	Late radiation-induced heart disease after radiotherapy. Clinical importance, radiobiological mechanisms and strategies of prevention. <i>Radiotherapy and Oncology</i> , 2011, 100, 160-166.	0.6	103
12	Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2013, 109, 13-20.	0.6	103
13	Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 485-491.	0.6	101
14	Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine. <i>Journal of Nuclear Medicine</i> , 2007, 48, 973-980.	5.0	92
15	Radiotherapy for High-Grade Gliomas. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 401-407.	2.0	90
16	Stereotactic body radiotherapy for oligo-metastatic liver disease: Influence of pre-treatment chemotherapy and histology on local tumor control. <i>Radiotherapy and Oncology</i> , 2017, 123, 227-233.	0.6	85
17	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021, 16, 278-288.	1.1	82
18	How we treat patients with leptomeningeal metastases. <i>ESMO Open</i> , 2019, 4, e000507.	4.5	79

#	ARTICLE	IF	CITATIONS
19	Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. <i>Annals of Oncology</i> , 2018, 29, 1431-1436.	1.2	73
20	The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. <i>BMC Cancer</i> , 2019, 19, 173.	2.6	68
21	First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia. <i>Radiotherapy and Oncology</i> , 2020, 152, 203-207.	0.6	59
22	CT radiomics and PET radiomics: ready for clinical implementation?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 355-370.	0.7	58
23	Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. <i>Radiotherapy and Oncology</i> , 2017, 123, 182-188.	0.6	55
24	Support Vector Machine-Based Prediction of Local Tumor Control After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 732-738.	0.8	54
25	Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. <i>Radiotherapy and Oncology</i> , 2020, 150, 30-39.	0.6	53
26	Stereotactic body radiotherapy for centrally located stageÂI NSCLC. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 125-132.	2.0	52
27	Recursive Partitioning Analysis (RPA) Class Does Not Predict Survival in Patients with Four or More Brain Metastases. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 16-20.	2.0	51
28	LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. <i>Acta OncolÃ³gica</i> , 2019, 58, 1275-1282.	1.8	50
29	Re-irradiation for Recurrent Primary Brain Tumors. <i>Anticancer Research</i> , 2016, 36, 4985-4996.	1.1	47
30	Evolution of treatment strategies for oligometastatic NSCLC patients â€“ A systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2019, 80, 101892.	7.7	45
31	Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 511-520.	0.8	42
32	Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 579-586.	0.8	40
33	Stereotactic Radiosurgery for Multiple Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2019, 21, 6.	1.8	38
34	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. <i>Radiotherapy and Oncology</i> , 2021, 159, 146-154.	0.6	37
35	Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. <i>Radiotherapy and Oncology</i> , 2018, 127, 246-252.	0.6	36
36	Treatment plan quality during online adaptive re-planning. <i>Radiation Oncology</i> , 2020, 15, 203.	2.7	36

#	ARTICLE	IF	CITATIONS
37	Repeated Courses of Radiosurgery for New Brain Metastases to Defer Whole Brain Radiotherapy: Feasibility and Outcome With Validation of the New Prognostic Metric Brain Metastasis Velocity. <i>Frontiers in Oncology</i> , 2018, 8, 551.	2.8	32
38	Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 104-112.	1.7	30
39	Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. <i>Radiotherapy and Oncology</i> , 2020, 142, 217-223.	0.6	29
40	Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis. <i>Radiation Oncology</i> , 2021, 16, 84.	2.7	29
41	Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases. <i>Radiation Oncology</i> , 2016, 11, 74.	2.7	28
42	Interdisciplinary Clinical Target Volume Generation for Cardiac Radioablation: Multicenter Benchmarking for the RAdiosurgery for VENTricular TACHycardia (RAVENTA) Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 745-756.	0.8	28
43	ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. <i>Radiotherapy and Oncology</i> , 2022, 173, 197-206.	0.6	28
44	Current status and recent advances in resection cavity irradiation of brain metastases. <i>Radiation Oncology</i> , 2021, 16, 73.	2.7	27
45	Optimization of combined proton+photon treatments. <i>Radiotherapy and Oncology</i> , 2018, 128, 133-138.	0.6	26
46	A national survey on radiation oncology patterns of practice in Switzerland during the COVID-19 pandemic: Present changes and future perspectives. <i>Radiotherapy and Oncology</i> , 2020, 150, 1-3.	0.6	26
47	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2019, 129, 63-71.	2.0	25
48	Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia. <i>Heart Rhythm</i> , 2021, 18, 2137-2145.	0.7	25
49	Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 163-168.	0.8	23
50	Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study. <i>Cancer</i> , 2018, 124, 2001-2009.	4.1	23
51	Stereotactic Radiotherapy for the Management of Refractory Ventricular Tachycardia: Promise and Future Directions. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 108.	2.4	23
52	Interchangeability of radiomic features between [18F]FDG PET/CT and [18F]FDG PET/MR. <i>Medical Physics</i> , 2019, 46, 1677-1685.	3.0	22
53	Estimation of the $\hat{\mu}/\hat{\sigma}^2$ ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 210-216.	0.6	22
54	Distance to isocenter is not associated with an increased risk for local failure in LINAC-based single-isocenter SRS or SRT for multiple brain metastases. <i>Radiotherapy and Oncology</i> , 2021, 159, 168-175.	0.6	22

#	ARTICLE	IF	CITATIONS
55	Stereotactic radioablation of ventricular arrhythmias in patients with structural heart disease – A systematic review. <i>Radiotherapy and Oncology</i> , 2021, 162, 132-139.	0.6	22
56	Generalizability assessment of head and neck cancer NTCP models based on the TRIPOD criteria. <i>Radiotherapy and Oncology</i> , 2020, 146, 143-150.	0.6	21
57	Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency. <i>Radiotherapy and Oncology</i> , 2021, 159, 106-111.	0.6	21
58	Adhesion Molecule Expression and Function of Primary Endothelial Cells in Benign and Malignant Tissues Correlates with Proliferation. <i>PLoS ONE</i> , 2014, 9, e91808.	2.5	20
59	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. <i>ESMO Open</i> , 2020, 5, e000763.	4.5	20
60	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8510-8510.	1.6	20
61	Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study. <i>Radiotherapy and Oncology</i> , 2022, 168, 256-264.	0.6	20
62	Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. <i>Anticancer Research</i> , 2003, 23, 5117-23.	1.1	20
63	Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 841-849.	0.8	19
64	Re-irradiation in the thorax – An analysis of efficacy and safety based on accumulated EQD2 doses. <i>Radiotherapy and Oncology</i> , 2020, 152, 56-62.	0.6	19
65	Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 691-703.	2.8	18
66	Quality of Training in Radiation Oncology in Germany. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 239-244.	2.0	18
67	Effects of Insulin-Like Growth Factor-1 (IGF-1) and Amifostine in Spinal Cord Reirradiation. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 691-695.	2.0	17
68	Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018, 96, 64-72.	2.8	17
69	18F-FET PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, 113-117.	1.3	17
70	Head and neck radiotherapy on the MR linac: a multicenter planning challenge amongst MRIdian platform users. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1093-1103.	2.0	17
71	Gating has a negligible impact on dose delivered in MRI-guided online adaptive radiotherapy of prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 170, 205-212.	0.6	17
72	Innovative prevention strategies for radiation necrosis of the central nervous system. <i>Anticancer Research</i> , 2002, 22, 1017-23.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Spatiotemporal fractionation schemes for liver stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 125, 357-364.	0.6	15
74	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 636672.	2.8	15
75	Long-Term Results of Dose-Intensified Fractionated Stereotactic Body Radiation Therapy (SBRT) for Painful Spinal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 348-357.	0.8	15
76	Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results. <i>Radiotherapy and Oncology</i> , 2019, 132, 63-69.	0.6	13
77	Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis. <i>European Journal of Cancer</i> , 2020, 124, 194-203.	2.8	13
78	Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 16, 109-112.	2.9	13
79	MR-Guided Adaptive Radiotherapy for Head and Neck Cancer: Prospective Evaluation of Migration and Anatomical Changes of the Major Salivary Glands. <i>Cancers</i> , 2021, 13, 5404.	3.7	13
80	Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience. <i>Radiation Oncology</i> , 2021, 16, 217.	2.7	13
81	The role of growth factors in central nervous system tumours. <i>Anticancer Research</i> , 2003, 23, 1681-6.	1.1	13
82	Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1513-1518.	0.8	12
83	Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 961.	2.8	12
84	Development of staffing, workload and infrastructure in member departments of the European Organisation for Research and Treatment of Cancer (EORTC) radiation oncology group. <i>Radiotherapy and Oncology</i> , 2021, 155, 226-231.	0.6	12
85	Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib. <i>Radiation Oncology</i> , 2015, 10, 29.	2.7	11
86	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020, 134, 75-85.	2.8	11
87	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. <i>Radiotherapy and Oncology</i> , 2021, 154, 269-273.	0.6	11
88	Management of multiple brain metastases: a patterns of care survey within the German Society for Radiation Oncology. <i>Journal of Neuro-Oncology</i> , 2021, 152, 395-404.	2.9	10
89	Single-isocenter versus multiple-isocenters for multiple lung metastases: Evaluation of lung dose. <i>Radiotherapy and Oncology</i> , 2022, 166, 189-194.	0.6	10
90	Evaluation of insulin-like growth factor-1 for prevention of radiation-induced spinal cord damage. <i>Growth Factors</i> , 2005, 23, 15-18.	1.7	9

#	ARTICLE	IF	CITATIONS
91	Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. <i>Clinical and Translational Oncology</i> , 2020, 22, 1698-1709.	2.4	9
92	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. <i>Clinical Lung Cancer</i> , 2021, 22, 579-586.	2.6	9
93	True abscopal effect in a patient with metastatic non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 194.	2.7	8
94	Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial. <i>Annals of Oncology</i> , 2019, 30, v591.	1.2	7
95	Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. <i>Journal of Neuro-Oncology</i> , 2019, 145, 339-347.	2.9	7
96	Comparison of beam segment versus full plan re-optimization in daily magnetic resonance imaging-guided online-adaptive radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 43-46.	2.9	7
97	High-dose re-irradiation of intracranial lesions – Efficacy and safety including dosimetric analysis based on accumulated EQD2Gy dose calculation. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 132-138.	1.7	7
98	SBRT in operable early stage lung cancer patients. <i>Translational Lung Cancer Research</i> , 2014, 3, 212-24.	2.8	7
99	Comprehensive summary and retrospective evaluation of prognostic scores for patients with newly diagnosed brain metastases treated with upfront radiosurgery in a modern patient collective. <i>Radiotherapy and Oncology</i> , 2022, 172, 23-31.	0.6	7
100	Acceleration of Normal-Tissue Damage Expression by Early Stimulation of Cell Proliferation in Rat Spinal Cord. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 680-684.	2.0	6
101	Development of a Score Predicting Survival after Palliative Reirradiation. <i>Journal of Oncology</i> , 2014, 1-7.	1.3	6
102	Dosimetric comparison of protons vs photons in re-irradiation of intracranial meningioma. <i>British Journal of Radiology</i> , 2019, 92, 20190113.	2.2	6
103	In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO). <i>Scientific Reports</i> , 2021, 11, 4590.	3.3	6
104	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 11566-11566.	1.6	5
105	Long-Term Survival in Metastasized Leiomyosarcoma: A Case Report and Review of the Literature. <i>Tumori</i> , 2015, 101, e141-e144.	1.1	4
106	Hippocampal Avoidance and Memantine for Whole-Brain Radiotherapy: Long-Term Follow-Up Warranted. <i>Journal of Clinical Oncology</i> , 2020, 38, 3454-3455.	1.6	4
107	Margin calculation for multiple lung metastases treated with single-isocenter SBRT. <i>Radiotherapy and Oncology</i> , 2021, 162, 105-111.	0.6	4
108	Adding cetuximab to stereotactic radiotherapy for non-small cell lung cancer might reduce local failure rates. <i>Medical Hypotheses</i> , 2012, 78, 420-422.	1.5	3

#	ARTICLE	IF	CITATIONS
109	Distinct Cerebrovascular Reactivity Patterns for Brain Radiation Necrosis. <i>Cancers</i> , 2021, 13, 1840.	3.7	3
110	Single-institution analysis of the prevalence, indications and outcomes of end-of-life radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 26-30.	1.7	3
111	Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiation. <i>Anticancer Research</i> , 2007, 27, 2353-7.	1.1	3
112	Late residual gamma-H2AX foci in murine spinal cord might facilitate development of response-modifying strategies: a research hypothesis. <i>Anticancer Research</i> , 2011, 31, 561-4.	1.1	3
113	Predicting Adverse Radiation Effects in Brain Tumors After Stereotactic Radiotherapy With Deep Learning and Handcrafted Radiomics. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
114	Stereotactic ablative radiotherapy for inoperable stage I NSCLC. <i>Lancet Oncology</i> , The, 2012, 13, 746-748.	10.7	2
115	Correspondence on Rajyaguru et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2561-2562.	1.6	2
116	Pathologic Features of Tumor Activity and Stability in Uveal Melanoma Specimens after Fractionated CyberKnife Radiosurgery. <i>Pathology and Oncology Research</i> , 2019, 25, 731-740.	1.9	2
117	Radiotherapy for glioblastoma patients with poor performance status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2127-2136.	2.5	2
118	Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 107-111.	1.7	2
119	A Multi-Institutional Estimation of Interobserver Variability in Glioblastoma Delineation in the EORTC-1709-BTG /CCTG CE.8 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E617-E618.	0.8	1
120	In Regard to Ohri etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 249-250.	0.8	1
121	Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. <i>Neuro-Oncology</i> , 2021, 23, 1612-1613.	1.2	1
122	Postoperative radiotherapy for meningiomas â€“ a decision-making analysis. <i>BMC Cancer</i> , 2022, 22, 492.	2.6	1
123	Prospective assessment of stress and health concerns of radiation oncology staff during the COVID-19 pandemic. <i>Clinical and Translational Radiation Oncology</i> , 2022, 35, 110-117.	1.7	1
124	P2.05-044 Influence of Technological Advances and Institutional Experience on Outcome of Stereotactic Body Radiotherapy for Lung Metastases. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1058-S1059.	1.1	0
125	CMET-26. DIAGNOSTIC VALUE OF FDG-PET/CT FOR PATIENTS WITH BRAIN METASTASIS FROM UNKNOWN PRIMARY SITE. <i>Neuro-Oncology</i> , 2017, 19, vi44-vi44.	1.2	0
126	MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA. <i>Neuro-Oncology Advances</i> , 2019, 1, i17-i17.	0.7	0

#	ARTICLE	IF	CITATIONS
127	MLTI-19. VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH BRAIN METASTASES: THE PICOS SCORE. <i>Neuro-Oncology Advances</i> , 2019, 1, i18-i18.	0.7	0
128	MLTI-09. UNDERWEIGHT AND WEIGHT LOSS ARE PREDICTORS OF POOR OUTCOME IN PATIENTS WITH BRAIN METASTASIS. <i>Neuro-Oncology Advances</i> , 2019, 1, i16-i16.	0.7	0
129	SP-0695 Systemic treatment as alternative or addition to radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 133, S360.	0.6	0
130	Leukoencephalopathy after Prophylactic Whole-Brain Irradiation with or without Hippocampal Sparing: A Long-Term MRI Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E79.	0.8	0
131	Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14062-e14062.	1.6	0
132	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2532-2532.	1.6	0
133	Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicity. <i>Anticancer Research</i> , 2007, 27, 183-7.	1.1	0